Variability in Response to Cardiovascular Drugs

被引:15
|
作者
Eldesoky, Ehab S. [1 ]
Derendorf, Hartmut [2 ]
Klotz, Ulrich [3 ]
机构
[1] Assiut Univ, Fac Med, Dept Pharmacol, Pharmacol, Assiut, Egypt
[2] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
来源
CURRENT CLINICAL PHARMACOLOGY | 2006年 / 1卷 / 01期
关键词
D O I
10.2174/157488406775268273
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular drugs are characterized by wide inter-individual variability in dose/plasma concentration/response (therapeutic and/or toxic) relationships. Therefore, some patients achieve good therapeutic response to their drug therapy, while others do not. Also, some patients experience adverse effects, which vary from mild to life-threatening. The source of variability in patients' response to cardiovascular drugs may be of pharmacokinetic and/or pharmacodynamic origin. Many factors can potentially affect both of them such as genetics, gender, age, disease state, environmental factors like smoking and food, possible drug-drug interactions, and ethnicity (race). Cardiovascular pharmacogenomics is a new field that focus on the roles of genetic polymorphisms in drug metabolizing enzymes and drug targets in development of variable drug response.
引用
收藏
页码:35 / 46
页数:12
相关论文
共 50 条